

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.



Touyun Biotech Group Limited
透雲生物科技集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

VOLUNTARY ANNOUNCEMENT
STRATEGIC COOPERATION AGREEMENT WITH SHENZHEN UNIVERSITY
FOR THE JOINT DEVELOPMENT OF THE CHLAMYGLUTIDE PROJECT

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Touyun Biotech Group Limited (the “**Company**”) on a voluntary basis to inform its shareholders and potential investors of the latest business development of the Group.

The Board is pleased to announce that on 15 April 2026, Shanxi Touyun Biotechnology Co., Ltd* (“**Shanxi Touyun**”), a wholly owned subsidiary of the Company and Shenzhen University (“**SZU**”) entered into a Strategic Cooperation Agreement for the Transformation of Scientific and Technological Achievements (the “**Agreement**”).

The Agreement

Pursuant to the Agreement, Shanxi Touyun and SZU will jointly establish “SZU-Touyun Biotech Chlamydomonas reinhardtii Joint Research Centre” (the “**Joint Research Centre**”), which is a non-legal entity research and development platform. The cooperation term is five years, with automatic renewal upon expiry. The Joint Research Centre will be dedicated to establishing a China Chlamydomonas reinhardtii germplasm resource conservation center, a synthetic biology toolbox, a pilot-scale platform, and a centre for talent cultivation and academic exchange. Shanxi Touyun will provide SZU with a total cooperation fund of RMB5 million, payable over five years at RMB1 million per year, for the research and operating expenses of the Joint Research Centre.

The first key collaboration project is SZU’s patented achievement entitled “*An engineered strain of Chlamydomonas reinhardtii stably expressing human GLP-1RA and its construction method and application* (一種穩定表達人源GLP-1RA的萊茵衣藻工程株及構建方法與應用)(CN2025115510147)”, hereinafter referred to as the “**Chlamyglutide**” project, for pilot-scale development, regulatory approval for biopharmaceutical products, and industrial application at Shanxi Touyun. Pursuant to the Agreement, SZU (including the inventor team) will receive a certain percentage of the total sales revenue of the Chlamyglutide Project products as future income. Shanxi Touyun will be responsible for the pilot-scale production, regulatory approval for manufacturing and clinical use, as well as large-scale production and sales of the project. SZU will provide the documents required for regulatory compliance, the engineered algal strains required for production, technical know-how documents such as product application instructions, and provide corresponding professional technical training to Shanxi Touyun’s production and technical personnel.

Shanxi Touyun and SZU will enter into separate agreements regarding intellectual property rights, strain management, and confidentiality obligations to ensure the proper protection of collaboration outcomes.

Background of Cooperation with SZU

SZU is a comprehensive university established in 1983. Since establishing its *Chlamydomonas reinhardtii* synthetic biology research group in 1999, SZU has published over 400 research papers, ranking first in China and has successfully constructed China’s first engineering algal strain bank for medicinal single-cell eukaryotic microalgae. SZU has successfully developed the patented achievement Chlamyglutide based on the *Chlamydomonas reinhardtii* model platform.

The Group is the world’s only technology-based company capable of large-scale fermentation production of *Chlamydomonas reinhardtii*. Its Shanxi Changzhi plant, with an annual capacity of 4,000 tons of *Chlamydomonas reinhardtii* powder, is already in production. Both parties have agreed to form a long-term strategic partnership, with the Group serving as the transformation base for SZU’s *Chlamydomonas reinhardtii* research achievements, will work together to build a world-class *Chlamydomonas reinhardtii* synthetic biology tool platform and bio-manufacturing platform.

REASONS FOR AND BENEFITS OF ENTERING INTO THE AGREEMENT

Entering into the Agreement will grant the Group exclusive cooperation opportunities with world-leading patents and top synthetic biology teams, ensuring the continuous launch of high-value products like Chlamyglutide. The Agreement also ensures the Group holds priority or exclusive rights to commercialize relevant technologies, preventing competitors from acquiring key intellectual property. This synergy combines SZU’s research strength with Shanxi Touyun’s production facilities and global patents to create a seamless rapid channel from research to mass production.

In conclusion, the Board considers that the collaboration under the Agreement constitutes a transaction of a revenue nature conducted in the ordinary and usual course of business of the Group for the advancement of the research, development and commercialisation of its core business of Chlamydomonas reinhardtii products. The terms of the collaboration are on normal commercial terms, are fair and reasonable, and are in the interests of the Company and its shareholders as a whole.

As the specific outcomes under the Agreement are subject to uncertainties, shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 15 April 2026

As at the date of this announcement, the Board comprises:

Executive Directors

Mr. Wang Liang (*Chairman*)
Mr. Du Dong

Non-executive Directors

Mr. Chen Hui
Ms. Tian Yuze
Mr. Zhang Lele

Independent Non-executive Directors

Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen

** for translation purpose only.*